Drug Trial Radar · NCT03439254
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
919
Actual
Start
Aug 30, 2017
Primary completion
Sep 8, 2022
Study completion Sep 8, 2022
Sponsor
- Lead sponsor
- Intercept PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.
Conditions
- Compensated Cirrhosis
- Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg)Drug
Tablets administered orally once daily.
Obeticholic acid (10 mg to 25 mg)Drug
Tablets administered orally once daily.
PlaceboDrug
Tablets administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- DB Phase: Number of Participants Who Were Responders and Showed Improvement in Fibrosis by at Least 1 Stage Without Worsening of Nonalcoholic Steatohepatitis (NASH)Time frame: Up to 18 months
- OLE Phase: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 12 months
- OLE Phase: Change From Baseline to Month 12 in Liver Stiffness Measurement (LSM)Time frame: Baseline and up to Month 12
- OLE Phase: Fibrosis-4 (FIB-4) at BaselineTime frame: Baseline (Day 1)
- OLE Phase: Enhanced Liver Fibrosis (ELF) at BaselineTime frame: Baseline (Day 1)
- OLE Phase: Number of Participants Reporting All-cause MortalityTime frame: Up to Month 12
- OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Ascites, Hepatocellular Carcinoma (HCC) and Non-liver Related DeathTime frame: Up to 12 months
- OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Worsening of Child-Pugh ScoreTime frame: Up to 12 months
- OLE Phase: Number of Participants With Adjudicated Liver Related Clinical Outcomes: Model for End-Stage Liver Disease (MELD) Score ≥15Time frame: Up to 12 months
Locations
192 sites in 12 countries. Site status is shown where the registry gives one.
Digestive Health Specialists of the Southeast
Dothan, Alabama
Objective GI d/b/a North Alabama GI Research Center
Madison, Alabama
Arizona Liver Health
Chandler, Arizona
Arizona Liver Health
Glendale, Arizona
The Institute for Liver Health
Tucson, Arizona
Liver Wellness Center
Little Rock, Arkansas
Arkansas Gastroenterology
North Little Rock, Arkansas
Hope Clinical Research
Canoga Park, California
University of California, San Francisco-Fresno
Fresno, California
Scripps Whittier Diabetes Institute
La Jolla, California
eStudySite
La Mesa, California
Keck Hospital of USC
Los Angeles, California
Cedars-Sinani Medical Center
Los Angeles, California
Palmtree Clinical Research, INC.
Palm Springs, California
Stanford University Medical Center
Palo Alto, California
California Liver Research Institute
Pasadena, California
Inland Empire Liver Foundation
Rialto, California
University of California, Davis Medical Center
Sacramento, California
Kaiser Permanente Sacramento Medical Center
Sacramento, California
University of California, San Francisco
San Francisco, California
University of Colorado Denver and Hospital
Aurora, Colorado
Peak Gastroenterology Associates
Colorado Springs, Colorado
South Denver Gastroenterology, PC
Englewood, Colorado
Innovative Medical Research of South Florida, Inc.
Aventura, Florida
Hi Tech and Global Research LLC
Coral Gables, Florida
Nature Coast Clinical Research
Inverness, Florida
UF Health Jacksonville-Gastroenterology Emerson
Jacksonville, Florida
Mayo Clinic Florida
Jacksonville, Florida
Schiff Center for Liver Diseases/University of Miami
Miami, Florida
Sensible Healthcare, LLC
Ocoee, Florida
Innovation Medical Research Center
Palmetto Bay, Florida
Gastroenterology Associates of Pensacola, PA
Pensacola, Florida
Tampa General Medical Group
Tampa, Florida
Guardian Angel Research Center, INC
Tampa, Florida
Florida Medical Clinic, P.A
Zephyrhills, Florida
Summit Clinical Research, LLC
Athens, Georgia
The Emory Clinic (TEC)
Atlanta, Georgia
Gastrointestinal Specialists of Georgia
Marietta, Georgia
Grand Teton Research Group, PLLC
Idaho Falls, Idaho
Rush University Medical Center
Chicago, Illinois
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.